Rationally Engineered Small Molecules: Pharmacophore Modeling and Molecular Docking Studies Targeting Toxic...

Area of Science:

• Neuroscience
• Computational Chemistry
• Drug Discovery

Background:

• Huntington's disease (HD) is a progressive neurodegenerative disorder driven by mutant huntingtin protein (mHTT) aggregation.
• The polyglutamine (polyQ) tracts and N-terminal domain (N17) of mHTT are key aggregation sites.
• Targeting mHTT aggregation presents a potential therapeutic strategy for HD.

Purpose of the Study:

• To identify small-molecule inhibitors capable of binding to aggregation-prone regions of mHTT.
• To computationally screen for compounds that can interfere with mHTT aggregation.
• To lay the groundwork for novel therapeutic interventions for Huntington's disease.

Main Methods:

• Active sites in polyQ regions and the N17 domain were identified using CASTp.
• Pharmacophore models were developed based on the glutamate inhibitor 6-Diazo-5-oxo-L-norleucine (DON).
• Ligand screening, molecular docking, and ADME/Toxicity analyses were performed.

Main Results:

• Ten DON-like ligands exhibited favorable pharmacophore characteristics.
• Five compounds demonstrated strong binding affinities to the polyQ region via molecular docking.
• The top five candidates showed acceptable pharmacokinetic profiles and drug-likeness.

Conclusions:

• Five lead compounds show potential to inhibit mHTT aggregation, a hallmark of HD.
• Favorable binding and pharmacokinetic properties suggest these compounds warrant further investigation.
• Experimental validation is crucial to confirm the efficacy and safety of these in silico-identified inhibitors.